Opendata, web and dolomites

T-NHL SUPRESSORS SIGNED

Tumor suppressor pathways counteracting oncogenic immune receptor signaling in T-Cell Lymphoma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 T-NHL SUPRESSORS project word cloud

Explore the words cloud of the T-NHL SUPRESSORS project. It provides you a very rough idea of what is the project "T-NHL SUPRESSORS" about.

receptor    cell    experimental    survival    overarching    lymphomas    human    understudied    mature    constitutive    lymphoma    entities    mutations    functions    pathogenesis    oncogenic    enforce    dissect    model    suppressor    counteract    haploinsufficient    sub    function    inhibitory    hypothesis    therapies    largely    inhibit    signaling    physiological    pd    hodgkin    activation    negative    gain    defense    clone    thereby    conventional    regulators    insights    presumably    regulatory    nhls    undefined    proliferation    continuous    molecules    expansion    immune    molecular    inactivated    host    aggressive    significantly    lymphomagenesis    tcr    vivo    independent    cells    events    manner    nhl    drive       variants    malignant    programs    multiple    enforced    resistant    comprehensively    dependent    limited    hallmark    antigen    malignancies    fundamental    tumor    30    pathomechanisms    mechanisms    cancers    oncogenically    effector    identification    sensing    additionally    explore    mediated   

Project "T-NHL SUPRESSORS" data sheet

The following table provides information about the project.

Coordinator
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN 

Organization address
address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675
website: http://www.med.tu.muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙492˙937 €
 EC max contribution 2˙492˙937 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-ADG
 Funding Scheme ERC-ADG
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2024-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) coordinator 2˙492˙937.00

Map

 Project objective

T cell non-Hodgkin lymphomas (T-NHLs) are highly aggressive malignancies that are largely resistant to conventional therapies. T-NHLs remain significantly understudied, and their molecular pathogenesis is still not well defined. Comprehensive analysis of mature T-cell lymphomas has identified multiple gain-of-function mutations in T-cell receptor (TCR) signaling molecules as an overarching hallmark of T-NHL sub-entities. Under physiological conditions, these molecules control the expansion, survival and effector function of antigen sensing T cells for host defense. Presumably, the oncogenic TCR signaling variants in lymphoma enforce these TCR programs in a constitutive manner and thereby drive continuous proliferation and expansion of the malignant clone. However, experimental in vivo evidence for this hypothesis is still limited, and the negative regulatory tumor suppressor mechanisms that can counteract oncogenic T cell signaling remain largely undefined. We recently identified the inhibitory immune receptor PD-1 as a key haploinsufficient tumor suppressor in T-cell lymphoma that is inactivated in up to 30% of human cases. The overall goal of this proposal is to comprehensively model and dissect T-cell lymphomagenesis driven by oncogenically enforced T-cell receptor pathways and to identify the PD-1 dependent and independent tumor suppressor mechanisms that inhibit these events. We will additionally explore the functions of new negative regulators within the PD-1 pathway or related pathways in antigen-mediated T cell activation. We expect that our results will provide fundamental new insights into the molecular pathomechanisms of highly aggressive T cell cancers and additionally lead to the identification of new negative regulators of antigen-mediated T cell activation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "T-NHL SUPRESSORS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "T-NHL SUPRESSORS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More